
NOSO-502
NOSO-502 is the first clinical candidate in the novel antibiotic class called Odilhorhabdins, inhibiting the bacterial ribosome with a new mechanism of action.
BVL-GSK098
Boosting Ethionamide efficacy and lowering the dose with small molecule transcriptional modulators to overcome multi-drug resistant tuberculosis infections and define a new place for Ethionamide in 1st-line TB treatments.
Gepotidacin tissue distribution
Demonstrating penetration of gepotidacin in tonsillar and prostate tissues.
ERA4TB-01
Molecule targeting cholesterol catabolism of mycobacteria.
ERA4TB-02
Compound targeting Mycobacterium tuberculosis tryptophan synthase, enzyme that catalyses the final two steps in the biosynthesis of tryptophan.
ERA4TB-03
Compounds targeting energy metabolism (electron chain transport).
ERA4TB-04
Compound targeting lysine transfer RNA synthase (LysS), which is an essential gene as assessed by transposon mutagenesis.
ERA4TB-06
Mycobacterial membrane protein Large 3 compounds with potent in vitro inhibitory and bactericidal activity against M tuberculosis.
ERA4TB-09
Natural product analogs active against Mycobacterium tuberculosis.
ERA4TB-10
Piperazinobenzothiazinone derivative as anti-mycobacterial compound that targets and covalently inhibits the enzyme Decaprenyl-phosphoryl-ribose 2'-epimerase.
BC1 back up
Lead optimization program on BC1 inhibitors.
RespiriTB
Mycothione reductase target exploration.
RespiriNTM
Progress novel assets (one First-in-human start) for Non-Tubercular Mycobacterium (NTM) that may act synergistically with Bedaquiline and cytochrome bc Drugs.